Cambridge Healthtech Institute’s Fifteenth Annual
Advancing Multispecific Antibodies to the Clinic
Creating the Next Wave of Cures
May 11-12, 2027
The repertoire of multispecific antibodies is expanding and new mechanisms to employ masking and conditional activation allow for greater precision and reduced toxicity and off-target effects. Applications outside oncology are increasing and include lupus, rheumatic diseases, Alzheimer’s, Macular Degeneration, Hemophilia, and Obesity, to name a few. A review of preclinical and clinical progress to date will be shared by the top experts in the industry. Don’t miss the Fifteenth Annual Advancing Multispecific Antibodies and Combination Therapy to the Clinic conference at the PEGS Boston Summit to gain insights into strategies that are bringing successful first-in-class molecules to market.
Coverage will include, but is not limited to:
- Reviewing results of multispecifics in preclinical and clinical development
- Assessing strategies for co-stimulatory bispecific antibodies, combination therapy, cell engagers and beyond
- Evaluating techniques for logic gating, masking, degraders, shuttles, and arming
- Expanding uses beyond cancer indications to autoimmune and beyond
- Advancing beyond T cell engagers to NK, gamma delta, macrophage, and other cell engagers
- Exploring emerging bi- and multispecific ADCs
The deadline for priority consideration is October 23, 2026.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation:
- To submit a podium presentation, please click here.
- To become a sponsor, click here.
- To present a poster, click here.
- To sign up to attend, click here.